Trimodal therapy (TMT) is included as an alternative to radical cystectomy (RC) for definitive management of muscle-invasive bladder cancer (MIBC) in current clinical guidelines. Moreover, a 2023 retrospective analysis reported similar oncologic outcomes between these treatments among patients deemed fit for RC.
Data regarding the comparative value of these treatments are lacking.
To evaluate the comparative cost-effectiveness of TMT and RC for treatment of MIBC.
This economic evaluation compared cost-effectiveness of treatments using a health transition state microsimulation model of patients with bladder cancer treated between 2005 and 2017 with 5- and 10-year horizons from a Medicare perspective. Model probabilities were informed by multicenter retrospective analyses published in 2023 comparing TMT with RC. The index patient was aged 71 years, with clinical stage T2-4aN0M0 MIBC, solitary tumor smaller than 7 cm, no or unilateral hydronephrosis, adequate bladder function, and lack of multifocal or extensive carcinoma in situ. Patients unfit for RC, radiation, or cisplatin-based chemotherapy were excluded.
TMT and RC.
Primary outcomes included effectiveness measured in quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICER) using a willingness-to-pay threshold of $100 000 per QALY. Sensitivity analyses were performed to assess the robustness of the model.
For the index patient, at 5 years, the average cost was $30 525 higher for TMT than RC. Average QALYs were 3.87 and 3.94 for RC and TMT, respectively. As such, TMT was not cost-effective at 5-year (ICER, $464 291 per QALY) or 10-year (ICER, $308 638 per QALY) time horizons. On 1-way sensitivity analyses, TMT would become cost-effective if (1) TMT costs were less than $17 605; or (2) TMT resulted in an 11.6% improvement in metastasis-free survival relative to RC.
In this economic evaluation study of TMT and RC for treatment of MIBC, TMT was associated with improved quality of life but was not cost-effective relative to RC at 5 and 10 years given higher treatment costs. These findings highlight the importance of developing policy initiatives that help reduce TMT costs and of providing patients with accurate expectations of long-term toxic effects to help guide preference-sensitive care.
JAMA network open. 2025 Jun 02*** epublish ***
Daniel D Joyce, Kevin M Wymer, John A Graves, Stephen A Boorjian, John L Gore, Ali Raza Khaki, Ann C Raldow, Stephen B Williams, Angela B Smith, Vidit Sharma
Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee., Department of Urology, Mayo Clinic, Rochester, Minnesota., Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee., Department of Urology, University of Washington School of Medicine, Seattle., Department of Medicine, Division of Oncology, Stanford University, Stanford, California., Department of Radiation Oncology, University of California, Los Angeles., Division of Urology, Department of Surgery, The University of Texas Medical Branch, Galveston., Department of Urology, University of North Carolina at Chapel Hill.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/40549384